Clinical Trials · NCT04125836

A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

CompletedPhase 3Octreotide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Camurus AB
Enrollment
135
Start date
Oct 2019
Locations
68 sites, 11 countries
Primary endpoint
Characterization of adverse events (AEs)
View Octreotide compound reference